Use of CA9 gene single nucleotide polymorphisms to predict prognosis and treatment response of metastatic renal cell carcinoma
| العنوان: | Use of CA9 gene single nucleotide polymorphisms to predict prognosis and treatment response of metastatic renal cell carcinoma |
|---|---|
| المؤلفون: | M. de Martino, T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, R. R. Caliliw, Z. Li, F. F. Kabbinavar, A. J. Pantuck, A. S. Belldegrun |
| المصدر: | Journal of Clinical Oncology. 27:5003-5003 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Treatment response, Response to therapy, business.industry, Single-nucleotide polymorphism, Favorable prognosis, medicine.disease, Text mining, Renal cell carcinoma, Internal medicine, medicine, Cancer research, Cell cancer, business, Gene |
| الوصف: | 5003 Background: Carbonic anhydrase 9 gene (CA9) is located in a prognostically relevant chromosomal area on chromosome 9p and is encoding for one of the most significant protein markers in metastatic renal cell carcinoma (MRCC), CAIX. In contrast to CAIX protein, however, no efforts have been made to date to study CA9 gene in metastatic RCC. Here, we test the hypotheses that single nucleotide polymorphisms (SNPs) and mutations of the CA9 gene are associated with CAIX expression, response to immunotherapy and survival. Methods: Genomic DNA was extracted from frozen tumor samples of 54 patients with clear cell MRCC. All exons of the CA9 gene were PCR-amplified and sequenced. The antibody M75 was used to evaluate CAIX protein expression immunohistochemically. Statistical associations of CA9 gene status and CAIX protein expression with response to IL-2 based immunotherapy and overall survival were assessed with chi-square tests, t-tests, Kaplan-Meier survival estimates and Cox proportional hazards regression models. Results: CA9 reference SNP (rs) 2071676 was found in 59%, rs12553173 in 15%, rs3829078 in 11% and rs1048638 in 33% of the patients. The deletion c.376del393 was observed in two patients. CAIX expression was high (>85%) in 65% of the patients. None of the SNPs was significantly associated with CAIX expression. Patients with the C allele variant of rs12553173 had improved median survival (27.3 vs. 13.6 months, p = 0.0431) and a greater likelihood of response to IL-2 (57% vs. 22%, p = 0.081) Likewise, high CAIX expression was associated with longer median survival (25.5 vs. 8.5 months, p < 0.0001) and a greater IL-2 response rate (37% vs. 8%, p = 0.070). In a multivariate Cox model, both C allele variant of CA9 SNP rs12553173 and CAIX expression were retained as independent prognostic factors. Conclusions: CA9 SNPs are frequently found in patients with MRCC. The C allele variant of rs12553173 is associated with improved overall survival and a greater likelihood of response to IL-2. CA9 rs12553173 and CAIX are both independent prognostic factors of overall survival and complementary in predicting prognosis of MRCC. No significant financial relationships to disclose. |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::bd87ea071ffae8b12d358da43bba979bTest https://doi.org/10.1200/jco.2009.27.15_suppl.5003Test |
| رقم الانضمام: | edsair.doi...........bd87ea071ffae8b12d358da43bba979b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|